Can Europe afford not to implement evidence-based medicine in heart failure ?
Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Cologne, DEU, 1997/05/26.
Technological change in cardiovascular medicine is extremely rapid and is likely to continue to accelerate.
Society, of course, demands that new products and services are clinically effective in combating disease, reducing disability and extending life.
Society also requires them to be cost-effective.
Within this framework there is a vital need to produce authoritative information to assist in making very important healthcare decisions.
A strategy for assessing both the effectiveness and the economics of cardiovascular disease management programmes has four discrete, mutually reinforcing tasks : (1) identifying the technologies that need to be assessed, (2) collecting data on the selected technologies, (3) synthesizing the data collected, and (4) disseminating the information collected.
There is no single strategy to prevent a global financial crisis in heart failure care.
However, a set of recommendations have been proposed as a means to overcome major obstacles.
These recommendations have been elaborated mainly from a practical point of view and, while they are not meant to be exhaustive, they may represent an agenda for action.
Future research, and especially experience relating to the economics and outcomes of heart failure care developments, will be of utmost interest and may act as a basis for further healthcare decisions.
Mots-clés Pascal : Insuffisance cardiaque, Europe, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Peptidases, Hydrolases, Enzyme, Inhibiteur enzyme, Analyse coût efficacité, Economie santé, Politique sanitaire, Chimiothérapie, Traitement, Pronostic, Homme, Vasodilatateur, Appareil circulatoire pathologie, Cardiopathie, Angiotensin converting enzyme
Mots-clés Pascal anglais : Heart failure, Europe, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Peptidases, Hydrolases, Enzyme, Enzyme inhibitor, Cost efficiency analysis, Health economy, Health policy, Chemotherapy, Treatment, Prognosis, Human, Vasodilator agent, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0033160
Code Inist : 002B02F04. Création : 31/05/1999.